Formulation Development
DEVELOPMENT TIMELINES – Drug Development Times, What it Takes – Part 1
Josef Bossart, PhD, explains how accurately estimating a product’s clinical development timelines is more than simply adding up the individual timelines, almost always optimistic. You need to “know” the numbers, not just calculate them.
BIOPROCESSING – A New Era: Why the Time Has Come for Biopharma to Move to Continuous Bioprocessing
Dr. Martin Smith explains why the pharma industry must embrace continuous processing if it’s to survive and thrive in an era of global personalized medicine.
EXECUTIVE INTERVIEW – Foamix Pharmaceuticals: Delivering Pharmaceuticals to the Skin Through a Foam
David Domzalski, Chief Executive Officer of Foamix, discusses his company’s innovative approach to drug delivery using foam to treat dermatological conditions, like acne and rosacea.
OLIGONUCLEOTIDE DELIVERY – Dectin-1 Receptor-Mediated Delivery of Oligonucleotide Drugs Complexed With Schizophyllan Dendritic Cells & Macrophages
Kenji Arima, PhD, and Akihiko Watanabe, PhD, introduce NapaJen Pharma’s technology with a specific focus on solving some of the current challenges of oligonucleotide therapeutics.
MARKET BRIEF – Tumor-Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy
Cheryl L. Barton, PhD, and Bianca Piachaud-Moustakis, PhD, believe the role of TIL therapy as an anticancer therapy in melanoma and possibly other solid tumors holds great promise and could become a viable course of treatment in the future.
2020 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
CDMO SELECTION – Ready to Launch: Developing Your Biologic With an Eye Toward Commercial Supply
Stacey Treichler, PhD, believes the development process for new biologics is complex and requires a substantial amount of time and resources, and reviews some of the areas where careful choice of CDMO is key, including cell line development and cGMP manufacturing capabilities, and how an integrated approach can be beneficial.
CONTINUOUS MANUFACTURING – Continuous Manufacturing in Pharmaceuticals: Implications for the Generics Market
Kamna Jhamb, PhD, says the highly regulated nature of the pharmaceutical sector, and the low-risk-taking nature of this market, are the two main factors that have restrained the implementation of novel methods of manufacturing by pharmaceutical industries. However, the burgeoning demand for complex and innovative therapies and rising competition have led pharmaceutical manufacturers to reconsider their methods of manufacturing.
DRUG DEVELOPMENT EXECUTIVE – ProQR: Developing RNA Therapies for Rare Genetic Disorders
Daniel de Boer, Chief Executive Officer of ProQR, discusses the use of RNA technology to directly target the underlying cause of genetic diseases.
MODIFIED RELEASE – Alternative Strategies for Development of Modified-Release Dosage Forms
Andy Lewis, PhD, discusses a range of available formulation technologies, the challenges in MR formulation development, and the use of a design-space approach with on-demand manufacturing.
EXCLUSIVE ONLINE CONTENT
For a CDMO, Flexibility & Adaptability Are Key Attributes to Navigate the Evolving Healthcare Landscape
The healthcare landscape continues to change at a rapid pace. The strong growth in the number of complex drugs, new therapeutic approaches and technologies, pricing issues and….
Saama Makes State-of-the-Art Clinical Analytics Platform Available to Integrate Data From All Organizations Investigating COVID-19 Treatments
Saama Technologies, Inc. recently announced it will contribute its AI-powered Life Science Analytics Cloud (LSAC) technology platform to establish the EndPandemic National Data Consortium…..
Horizon Discovery & Pharmahungary Report Positive Early Stage Results for Novel Micro-RNA Therapeutic
Horizon Discovery Group plc and Pharmahungary Group recently announced positive early stage results for a novel micro-RNA therapeutic for…………..
Altimmune & the University of Alabama Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine
Altimmune, Inc. recently announced it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose…..
Lonza Launches New TheraPEAK SfAAV Medium to Boost & Optimize the Production of AAV in Sf9 Insect Cells
Lonza recently announced the launch of the TheraPEAK SfAAV Medium, the first chemically defined, non-animal origin medium designed specifically for the production of….